1-4 of 4
C. Ravoet
Close
Sort by
Journal Articles

Bortezomib + Low Dose Cytarabine in Int-2 and High Risk MDS. Interim Results of a Phase I/II Trial by the GFM.

Shanti Natarajan, Pierre Fenaux, Norbert Vey, A. Guerci, I. Coulibaly, A. Charbonnier, C. Ravoet, S. Courby, G. Etienne, M.P. Chaury, S. Cheze, A. Stamatoullas, L. Legros, E. Berger, A. Lescoute, S. Vaultier, F. Dreyfus
Journal: Blood
Blood (2007) 110 (11): 1453.
https://doi.org/10.1182/blood.V110.11.1453.1453
Published: 2007
Journal Articles

Lenalidomide (LEN) in INT 2 and High Risk MDS with DEL 5q. Interim Results of a Phase II Trial by the GFM.

S. Burcheri, MD, T. Prebet, MD, O. Beyne-Rauzy, MD, R.M. Mbida, MD, N. Hoarau, MD, L. Legros, MD, C. Ravoet, MD, F. Dreyfus, MD, A. Stamatoullas, MD, M.P. Chaury, MD, J. Delaunay, MD, G. Laurent, MD, N. Vey, MD, L. Ades, MD, C. Gardin, MD, Pierre Fenaux, MD
Journal: Blood
Blood (2007) 110 (11): 820.
https://doi.org/10.1182/blood.V110.11.820.820
Published: 2007
Journal Articles

Prognostic Factors and Response Duration in 419 MDS Treated with Erythropoietin±GCSF: The GFM Experience.

S. Park, C. Kelaidi, S. Grabar, O. Beyne-Rauzy, S. Cheze, V. Bardet, M. Escoffre-Barbe, C. Ravoet, A. Ferrant, N. Vey, H. Dombret, B. Mahe, L. Mannone, L. Legros, L. Aljassem, A. Stamatoullas, D. Vassilief, M.C. Quarre, L. Ades, V. Andrieux, S. Giraudier, S. de Botton, N. Casadevall, P. Fenaux, F. Dreyfus
Journal: Blood
Blood (2006) 108 (11): 522.
https://doi.org/10.1182/blood.V108.11.522.522
Published: 2006
Journal Articles

Predictive value of the steady-state peripheral blood progenitor cell (PBPC) counts for the yield of PBPC collected by leukapheresis after mobilization by granulocyte colony-stimulating factor (G-CSF) alone or chemotherapy and G-CSF [letter; comment]

B Husson, C Ravoet, M Dehon, G Wallef, N Hougardy, A Delannoy
Journal: Blood
Blood (1996) 87 (8): 3526–3528.
https://doi.org/10.1182/blood.V87.8.3526b.bloodjournal8783526b
Published: 1996